InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,591.96
(
0.00%
)
US TECH 100
18,993.60
(
0.89%
)
Dow Jones
41,335.05
(
0.00%
)
Brent Oil
78.89
(
0.16%
)
Bitcoin
59,484.84
(
0.15%
)
Post# of 252990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120347
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 224650

Monday, 04/15/2019 6:52:51 PM

Monday, April 15, 2019 6:52:51 PM

Post# of 252990

ASMB—Guess remains to be seen if 48-week data will look any better for the lead on HBsAg declines but, given all these follow-on drugs, I'm just going to continue to remain skeptical.

It may be that core inhibitors are indeed a propitious way to address HBV (especially when combined with a nuke), but that ASMB’s CpAM compounds are suboptimal compared to those from another company :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up